Clinical Observation of Labetalol Combined with Nifedipine in the Treatment of Gestational Hypertension
Expand
1.Jiaozuo People′s Hospital， Henan Jiaozuo 454000， China； 2.The Third Affiliated Hospital of Zhengzhou University， Henan Maternal and Child Health Hospital，Henan Zhengzhou 450052， China
Objective： To evaluate the clinical efficacy of labetalol combined with nifedipine in the treatment of gestational hypertension (GH) and to analyze its effects on blood pressure， coagulation function， and vascular endothelial function. Methods： A total of 113 patients with GH admitted to Jiaozuo People′s Hospital， Henan Province， from August 2022 to February 2025 were retrospectively included. Patients were assigned to the control group (n=56， labetalol monotherapy) or the experimental group (n=57， labetalol + nifedipine)， and treated for 2 weeks. Main outcome measures included blood pressure (SBP， DBP)， coagulation parameters (FIB， APTT，PT，TT)， endothelial function markers (IGF-1，sFlt-1，NO，ET-1)，adverse pregnancy outcomes， and drug-related adverse reactions. Results： The total effective rate was higher in the experimental group than in the control group (92.98% vs. 78.57%， P<0.05). After treatment， SBP， DBP， FIB， and ET-1 levels decreased， while APTT， PT， TT， IGF-1， sFlt-1， and NO levels increased in both groups (P＜0.05)， with greater improvements observed in the experimental group (P＜0.05). The incidence of adverse pregnancy outcomes was lower in the experimental group compared with the control group (14.04% vs. 30.36%， P＜0.05). The incidence of adverse drug reactions showed no significant difference between the two groups (12.28% vs. 8.93%， P＞0.05). Conclusion： Labetalol combined with nifedipine is more effective in controlling blood pressure in GH patients， improving coagulation and endothelial function， and reducing the risk of adverse pregnancy outcomes， with good safety. Further multicenter are warranted in mild-to-moderate GH patients excluding preeclampsia.
